Phase II study in advanced sarcoma: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin, and cis-dichlorodiammineplatinum(II) (CAP).
Twenty-eight patients with various histologic types of measurable metastatic sarcoma were randomly assigned to receive treatment with combination cyclophosphamide, doxorubicin (Adriamycin), and cis-dichlorodiammineplatinum(II) (CAP) or the single-agent, pyrazofurin. Patients who failed one arm of the protocol were eligible for cross-over treatment. Six of 24 patients treated with CAP achieved objective tumor regressions (25%), with a median duration of 11 months. None of 21 patients receiving pyrazofurin achieved a response. CAP is an effective, well-tolerated combination for the treatment of advanced sarcoma.